disturbed fat and glucose metabolism Metabolic syndrome
Conditions
Interventions
Subjects will consume in random order a) 200 mg fenofibrate together with 7.2 g
of sunflower oil placebo and b) 7.2 g fish oil together with 200 mg placebo
cellulose placebo and c) 200 mg cellulose
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Body Mass Index > 27 kg/mw or waist circumference > 88 cm (women) or >102 cm (men)
Exclusion criteria
Exclusion criteria: - BMI 8 mmol/l - Use of medication that can interact with fenofibrate (study medication), including: HMGCoA reductase inhibitors (statins, eg. lovastatin, pravastatin, simvastatin), anticoagulants (eg. acenocoumarol, phenindione, warfarin) - Hypersensitivity to (feno)fibrate products - Active cardiovascular disease like congestive heart failure or recent ( 3 kg in the past three months) - Impairment of renal function, as evidenced by increased serum creatinine >150 mmol/L - Hepatic diseases as manifested by ALT, AST, GGT, total bilirubin or ALP > 2 times the upper limit of normal - Abuse of drugs and/or alcohol - Pregnant or breast-feeding women - Participation in another biomedical study within 1 month prior to the start of this study - Having donated blood (as blood donor) within 1 month prior to start of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of PPARa related genes, markers of insulin resistance, serum lipid and lipoprotein profile and markers of inflammation. | — |
Countries
Netherlands
Outcome results
None listed